Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Key drug–drug interactions with direct-acting antiviral in HIV–HCV coinfection

Key drug–drug interactions with direct-acting antiviral in HIV–HCV coinfection Downloaded from http://journals.lww.com/co-hivandaids by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/04/2020 REVIEW URRENT Key drug–drug interactions with direct-acting PINION antiviral in HIV–HCV coinfection a b c,d Omar El-Sherif , Saye Khoo , and Caroline Solas Purpose of review We reviewed the most recent data on pharmacokinetic interactions between hepatitis C direct-acting antiviral (DAA) agents and HIV antiretrovirals (ARVs). Recent findings Drug interactions between DAAs and HIV ARVs are extrapolated from phase 1 drug–drug interaction (DDI) studies in healthy volunteers. Safety and efficacy data of DAA–ARV combinations are largely limited to the drug combinations permitted in phase 2 and 3 HIV–HCV coinfection trials. Paritapervir/ritonavir with ombitasvir and dasabuvir (3D) should not be coadministered with efavirenz, etravirine, elvitegravir/ cobicistat or with additional doses of ritonavir. Atazanavir, darunavir and rilpivirine require cautious monitoring when used with 3D. The combination of sofosbuvir and ledipasvir can be safely used with most ARVs, but there is a risk of hyperbilirubinaemia with atazanavir. Tenofovir exposure is significantly increased when used with sofosbuvir–ledipasvir and a boosted protease inhibitor or emtricitabine/ efavirenz, and therefore should be used with cautious monitoring for renal toxicity only when alternative therapy is not possible. Daclatasvir requires dosage modification with atazanavir, efavirenz and cobicistat. The coadministration of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV & AIDS Wolters Kluwer Health

Key drug–drug interactions with direct-acting antiviral in HIV–HCV coinfection

Download PDF
7 pages

Loading next page...
 
/lp/wolters-kluwer-health/key-drug-drug-interactions-with-direct-acting-antiviral-in-hiv-hcv-h2qdqxD03v

References (24)

Publisher
Wolters Kluwer Health
ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/COH.0000000000000185
Publisher site
See Article on Publisher Site

Abstract

Downloaded from http://journals.lww.com/co-hivandaids by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/04/2020 REVIEW URRENT Key drug–drug interactions with direct-acting PINION antiviral in HIV–HCV coinfection a b c,d Omar El-Sherif , Saye Khoo , and Caroline Solas Purpose of review We reviewed the most recent data on pharmacokinetic interactions between hepatitis C direct-acting antiviral (DAA) agents and HIV antiretrovirals (ARVs). Recent findings Drug interactions between DAAs and HIV ARVs are extrapolated from phase 1 drug–drug interaction (DDI) studies in healthy volunteers. Safety and efficacy data of DAA–ARV combinations are largely limited to the drug combinations permitted in phase 2 and 3 HIV–HCV coinfection trials. Paritapervir/ritonavir with ombitasvir and dasabuvir (3D) should not be coadministered with efavirenz, etravirine, elvitegravir/ cobicistat or with additional doses of ritonavir. Atazanavir, darunavir and rilpivirine require cautious monitoring when used with 3D. The combination of sofosbuvir and ledipasvir can be safely used with most ARVs, but there is a risk of hyperbilirubinaemia with atazanavir. Tenofovir exposure is significantly increased when used with sofosbuvir–ledipasvir and a boosted protease inhibitor or emtricitabine/ efavirenz, and therefore should be used with cautious monitoring for renal toxicity only when alternative therapy is not possible. Daclatasvir requires dosage modification with atazanavir, efavirenz and cobicistat. The coadministration of

Journal

Current Opinion in HIV & AIDS – Wolters Kluwer Health

Published: Sep 1, 2015

There are no references for this article.